Baxter 2021 Corporate Responsibility Report 60 Appendix 2030 Corporate Responsibility Goals Corporate Responsibility Commitment Empower Our Patients Protect Our Planet Champion Our People and Communities Introduction Cross-Cutting Commitments Appendix: Sustainability Accounting Standards Board Index (continued) TOPIC CODE SASB METRIC 2021 REPORTING Ethical Marketing HC-MS-270a.1 Total amount of monetary losses as a result of legal proceedings associated with false marketing claims In 2021, Baxter had no monetary losses due to legal proceedings associated with false marketing claims that were previously reported in any company Exchange Act filings. HC-MS-270a.2 Description of code of ethics governing promotion of off-label use of products Off-label promotion is strictly prohibited at Baxter. See the Baxter Code of Conduct and the Baxter Global Interactions Policy . See Ethics and Compliance for information about the company’s approach in this area. Product Design & Lifecycle Management HC-MS-410a.1 Discussion of process to assess and manage environmental and human health considerations associated with chemicals in products, and meet demand for sustainable products See Sustainable Design , Materials Use in Products and Packaging , Materials of Concern and Striving for Full Materials Disclosure for information about the company’s approach in this area. HC-MS-410a.2 Total amount of products accepted for takeback and reused, recycled, or donated, broken down by: (1) devices and equipment and (2) supplies See Product End-of-Life for product recovery data and information about the company’s approach in this area. Supply Chain Management HC-MS-430a.1 Percentage of (1) entity’s facilities and (2) Tier I suppliers’ facilities participating in third-party audit programs for manufacturing and product quality Between 2019 and 2021, approximately 40% of Baxter’s total facilities worldwide completed third-party audits based on ISO 13485 or ISO 9001 (including through the Medical Device Single Audit Program); approximately 50% completed ministry of health or equivalent audits (depending on location) related to manufacturing and product quality; and nearly 10% completed safety marking (such as CE marking) audits. As of Dec. 31, 2021, 29% of Baxter’s Tier I suppliers had obtained third-party certification. See Continually Improve Manufacturing Capabilities and Supplier Audits for related information. HC-MS-430a.2 Description of efforts to maintain traceability within the distribution chain Baxter has a range of systems and processes to maintain traceability of materials throughout the product supply and distribution chain: • Traceability of materials from suppliers to Baxter, and throughout the manufacturing process, is maintained utilizing electronic systems. • Products manufactured by Baxter are labeled with an identifier that is traceable from the manufacturing process to the customer and may utilize barcoding and serialization technology to facilitate electronic track-and-trace capability. Enterprise resource planning (ERP) systems are used to manage traceability to the point of sale. Baxter has business agreements with our wholesalers to ensure traceability is maintained within their distribution chains, and we can access related information if needed. • Baxter maintains a range of compliance-focused initiatives to help ensure all products are labeled as required by local and regional regulations to enable traceability. See section 7.11, Product Identification and Traceability of the Baxter Supplier Quality Standard and Customs Trade Partnership Against Terrorism program content in Industry Collaboration for more information. HC-MS-430a.3 Description of the management of risks associated with the use of critical materials See Baxter’s Position Statement on Conflict Minerals and our most recent Conflict Minerals Report . Business Ethics HC-MS-510a.1 Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption In 2021, Baxter had no monetary losses due to legal proceedings associated with bribery or corruption that were previously reported in any company Exchange Act filings. See Ethics and Compliance for information about the company’s approach in this area. HC-MS-510a.2 Description of code of ethics governing interactions with health care professionals See Baxter’s Global Interactions Policy and Ethics and Compliance for information about the company’s approach in this area. Baxter has adopted the AdvaMed Code of Ethics and also belongs to similar industry and professional associations around the world. See Professional Codes of Ethics and Industry Standards on Baxter’s Ethics and Compliance page for information.